|
XCUR | Exicure, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.19 |
| Leverage | 54.63% |
| Market Cap | $ 36.1m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -9.1m |
| Margin | -635.48% |
Exicure, Inc., a clinical-stage biotechnology company, develops therapies for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. The company is headquartered in Chicago, Illinois.